TriSalus Life Sciences, Inc. (TLSI)
NASDAQ: TLSI · Real-Time Price · USD
4.070
-0.050 (-1.21%)
Nov 20, 2024, 4:00 PM EST - Market closed
TriSalus Life Sciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 26.89 | 18.51 | 12.4 | 8.4 | 5.43 |
| Revenue Growth (YoY) | 67.92% | 49.31% | 47.58% | 54.60% | - |
| Cost of Revenue | 3.47 | 2.61 | 2.26 | 1.19 | 2.2 |
| Gross Profit | 23.42 | 15.91 | 10.14 | 7.21 | 3.24 |
| Selling, General & Admin | 48.09 | 40.55 | 25.22 | 17.02 | 13.06 |
| Research & Development | 22.37 | 29.51 | 21.36 | 14.22 | 15.83 |
| Operating Expenses | 70.45 | 70.06 | 46.58 | 31.24 | 28.88 |
| Operating Income | -47.03 | -54.15 | -36.44 | -24.03 | -25.65 |
| Interest Expense | -2.03 | -0.02 | -0 | -1.76 | -6.04 |
| Interest & Investment Income | 0.59 | 0.43 | 0.18 | - | - |
| Other Non Operating Income (Expenses) | -13.75 | -15.59 | -10.92 | -0.46 | -0.14 |
| EBT Excluding Unusual Items | -62.22 | -69.32 | -47.18 | -26.25 | -31.83 |
| Other Unusual Items | 2.45 | 10.29 | - | -2.59 | - |
| Pretax Income | -55.44 | -59.03 | -47.18 | -28.84 | -31.83 |
| Income Tax Expense | 0.01 | 0.01 | 0.01 | 0 | 0 |
| Net Income | -55.45 | -59.04 | -47.19 | -28.85 | -31.83 |
| Preferred Dividends & Other Adjustments | 0.8 | 4.24 | 2.83 | - | - |
| Net Income to Common | -56.25 | -63.28 | -50.02 | -28.85 | -31.83 |
| Shares Outstanding (Basic) | 24 | 9 | 0 | 9 | 8 |
| Shares Outstanding (Diluted) | 24 | 9 | 0 | 9 | 8 |
| Shares Change (YoY) | 578.00% | 2934.71% | -96.51% | 15.52% | - |
| EPS (Basic) | -2.31 | -6.73 | -161.55 | -3.25 | -4.15 |
| EPS (Diluted) | -2.31 | -6.73 | -161.55 | -3.25 | -4.15 |
| Free Cash Flow | -44.65 | -50.63 | -32.97 | -23.79 | -16.13 |
| Free Cash Flow Per Share | -1.84 | -5.39 | -106.48 | -2.68 | -2.10 |
| Gross Margin | 87.10% | 85.93% | 81.79% | 85.80% | 59.55% |
| Operating Margin | -174.88% | -292.53% | -293.91% | -286.06% | -471.95% |
| Profit Margin | -209.16% | -341.83% | -403.42% | -343.35% | -585.76% |
| Free Cash Flow Margin | -166.04% | -273.53% | -265.91% | -283.23% | -296.74% |
| EBITDA | -46.28 | -53.45 | -36.04 | -23.57 | -25.33 |
| EBITDA Margin | -172.08% | -288.74% | -290.70% | -280.54% | - |
| D&A For EBITDA | 0.75 | 0.7 | 0.4 | 0.46 | 0.32 |
| EBIT | -47.03 | -54.15 | -36.44 | -24.03 | -25.65 |
| EBIT Margin | -174.88% | -292.53% | -293.91% | -286.06% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.